blinatumomab: Clinical Trials

28 trials of blinatumomab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 recruiting, 7 active not recruiting, 4 not yet recruiting, 3 completed. 28 Phase 3, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 328Recruiting 12, Active not recruiting 7, Not yet recruiting 4, Completed 3, Terminated 1, Withdrawn 1
Phase 210Recruiting 6, Not yet recruiting 2, Active not recruiting 1, Completed 1

Follow blinatumomab: new trials by email Literature Review of blinatumomab trials Research Report on blinatumomab

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia
Phase 3RecruitingCharite University, Berlin, Germany7502026-09-012026-10-26
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL
BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2122026-08-092026-07-23
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3402026-05-182026-11-10
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab - Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant
Phase 2 / Phase 3RecruitingBambino Gesù Hospital and Research Institute10002026-01-072026-10-20
A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone - Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingAssistance Publique - Hôpitaux de Paris12002025-05-062026-02-10
Blinatumomab for Treatment of Refractory Myasthenia Gravis
Blinatumomab - Myasthenia Gravis
Phase 2 / Phase 3Not yet recruitingDa, Yuwei, M.D.22025-04-012025-03-25
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
olverembatinib - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China1502025-03-282025-09-03
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Blinatumomab, Reinduction-2 omission, Chemo-light Maintenance 2 - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Phase 2 / Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China30002025-03-032025-08-26
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B) - Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Phase 2 / Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China18002025-01-032026-07-23
Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)
Blinatumomab - Myasthaenia Gravis
Phase 2 / Phase 3Not yet recruitingZhongming Qiu102024-11-302024-11-12
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Blinatumomab - B-Cell Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingShanghai Jiao Tong University School of Medicine902024-05-212024-09-23
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Blinatumomab - Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Phase 3RecruitingPrincess Maxima Center for Pediatric Oncology1602022-12-152026-10-19
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen - Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Phase 3Active not recruitingAmgen3032021-11-022026-06-30
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Ponatinib + Blinatumomab, Chemotherapy + Imatinib - Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult
Phase 3Active not recruitingGruppo Italiano Malattie EMatologiche dell'Adulto2362021-09-082025-01-23
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 3Active not recruitingNational Cancer Institute (NCI)3482021-01-252026-11-12
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy - Leukemia, Acute Lymphoblastic
Phase 3RecruitingMats Heyman64302020-07-132026-08-12
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia
Phase 3WithdrawnNovartis Pharmaceuticals2020-06-052020-07-09
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Phase 3RecruitingChildren's Oncology Group59512019-10-312026-08-25
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Phase 3Active not recruitingNational Cancer Institute (NCI)67202019-07-032026-11-12

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Precursor Cell Lymphoblastic Leukemia-Lymphoma (16)  ·  Burkitt Lymphoma (9)  ·  Leukemia (4)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Recurrence (3)  ·  Leukemia, Biphenotypic, Acute (2)  ·  Neoplasms (2)  ·  Down Syndrome (1)  ·  Graft vs Host Disease (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoproliferative Disorders (1)  ·  Myasthenia Gravis (1)

Sponsors

Amgen (6)  ·  Institute of Hematology & Blood Diseases Hospital, China (4)  ·  National Cancer Institute (NCI) (4)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Bambino Gesù Hospital and Research Institute (1)  ·  Charite University, Berlin, Germany (1)  ·  Children's Oncology Group (1)  ·  Da, Yuwei, M.D. (1)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (1)  ·  Martin Schrappe (1)  ·  Mats Heyman (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Novartis Pharmaceuticals (1)  ·  Princess Maxima Center for Pediatric Oncology (1)  ·  Shanghai Jiao Tong University School of Medicine (1)

Countries

Australia (10)  ·  Italy (10)  ·  France (9)  ·  Israel (9)  ·  United States (9)  ·  Canada (8)  ·  Germany (8)  ·  Spain (8)  ·  Austria (7)  ·  Belgium (7)  ·  Czechia (7)  ·  Denmark (7)  ·  Netherlands (6)  ·  Puerto Rico (6)  ·  Sweden (6)

Top investigators

Xiaofan Zhu, MD (3)  ·  Arend von Stackelberg, Dr. med., MD (1)  ·  Franco Locatelli, Professor (1)  ·  Hiroto Inaba, MD, PhD (1)  ·  Janine Stutterheim, Dr (1)  ·  Jennifer L McNeer (1)  ·  Mark R Litzow (1)  ·  Martin Schrappe, MD (1)  ·  Mats Heyman, MD, PhD (1)  ·  Patrick A Brown (1)  ·  Sumit Gupta (1)  ·  Yishai Ofran (1)

Results publications

PMID 41671463, PMID 32289160, PMID 32546071, PMID 32589970, PMID 33542479, PMID 33651090, PMID 33844429, PMID 34161631, PMID 35129146, PMID 35501736, PMID 35622074, PMID 36000952, PMID 37141547, PMID 37257143, PMID 38841802, PMID 39047240, PMID 39214018, PMID 39651791, PMID 40568722, PMID 42154791, PMID 42748428, PMID 42832396, PMID 42874102

NIH funding

2025 (3), U10CA180886 (3), 2023 (2), U10CA180820 (2), 2014 (1), 2016 (1), U10CA021115 (1), U10CA098543 (1), U24CA196172 (1)